Posts tagged ‘Abiraterone MDV3100 Combination’
Sally Church on Pharma Strategy Blog has published a video blog (vlog) post on what’s hot in Prostate Cancer at the 2011 AUA (American Urological Association) annual meeting in Washington DC.
In her post, Sally reviews presentations by Charles Sawyers and Oliver Sartor. She discusses new prostate cancer products in development such as MDV3100 and custirsen (OGX-011), and how our understanding of basic biology may lead to new combinations in the future.
If you missed Sally’s video blog post, then you can watch it on Vimeo below. As Sally would say, “check it out!”
This Friday sees the start of the 2011 annual meeting of the American Urological Association (AUA) in Washington, DC. The meeting runs from May 14-19.
We expect the recent FDA approval of abiraterone acetate (Zytiga®) from Ortho Biotech (JNJ) to be hot news at the meeting as urologists seek to learn more about it’s use.
Icarus Consultants will be in our Nation’s Capital for AUA, so should you be interested in meeting up, please contact us.